Stocklytics Platform
Asset logo for symbol NXL
Nexalin Technology
NXL54
$1.24arrow_drop_up5.98%$0.07
Penny Stock
Asset logo for symbol NXL
NXL54

$1.24

arrow_drop_up5.98%

Performance History

Chart placeholder
Key Stats
Open$1.15
Prev. Close$1.17
EPS-0.67
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$12.49M
PE Ratio-
LOWHIGH
Day Range1.13
1.30
52 Week Range0.25
4.05
Ratios
Revenue-
EBITDA Margin %-
EPS-0.67

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$805.15
Perf. (24h)
arrow_drop_down1.95%-$16.03
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$570.00
Perf. (24h)
arrow_drop_up1.84%$10.32
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.66
Perf. (24h)
arrow_drop_up0.63%$1.02
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.19
Perf. (24h)
arrow_drop_up1.65%$3.02
Market Cap$326.96B

About Nexalin Technology (NXL)

NEXALIN TECHNOLOGY INC., a Nevada corporation (the "Company" or "Nexalin"), is an emerging growth company specializing in the development and commercialization of advanced medical devices and equipment. The Company is focused on the innovative treatment of mental health disorders through its proprietary Nexalin therapy system. Nexalin therapy is a non-invasive neuromodulation therapy that uses gentle electrical stimulation to the brain to alleviate symptoms of depression, anxiety, and insomnia.
The Nexalin therapy system has been clinically proven to effectively treat a wide range of mood and sleep disorders, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, and chronic insomnia. Unlike traditional treatments such as medication and psychotherapy, Nexalin therapy is drug-free, painless, and has no known side effects. The therapy works by stimulating the production of neurotransmitters in the brain, which are chemicals that help regulate mood and sleep patterns.
Websitecall_made
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Mark White
Headquarters
Houston
Employees
6
Exchange
NASDAQ
add Nexalin Technology to watchlist

Keep an eye on Nexalin Technology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Nexalin Technology 's (NXL) price per share?
The current price per share for Nexalin Technology (NXL) is $1.24. The stock has seen a price change of $0.07 recently, indicating a 5.98% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Nexalin Technology (NXL)?
For Nexalin Technology (NXL), the 52-week high is $4.05, which is 226.61% from the current price. The 52-week low is $0.25, the current price is 390.12% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Nexalin Technology (NXL) a growth stock?
Nexalin Technology (NXL) has shown an average price growth of 0.41% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nexalin Technology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Nexalin Technology (NXL) stock price performance year to date (YTD)?
As of the latest data, Nexalin Technology (NXL) has a year-to-date price change of 211.32%. Over the past month, the stock has experienced a price change of -54.58%. Over the last three months, the change has been -13.89%. Over the past six months, the figure is 253.68%.
help
Is Nexalin Technology (NXL) a profitable company?
Nexalin Technology (NXL) has a net income of -$4.65M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.36K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$5.7M. Furthermore, the EBITDA is -$5.98M.
help
What is the market capitalization of Nexalin Technology (NXL)?
Nexalin Technology (NXL) has a market capitalization of $12.49M. The average daily trading volume is 202.5K, indicating the stock's liquidity and investor engagement.

News

Nexalin Technology Announces Closing of $5.2 Million Public Offering
ADVISORY
7/1/2024

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Nexalin Technology Announces Pricing of $5.2 Million Public Offering
INITIAL PUBLIC OFFERINGS
6/28/2024

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
ADVISORY
6/20/2024

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
ADVISORY
PRODUCT / SERVICES ANNOUNCEMENT
6/13/2024

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
ADVISORY
CLINICAL STUDY
6/3/2024

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
ADVISORY
5/22/2024

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level